Ipsen S.A. (FRA:I7G)

Market Cap	12.95B +31.6%
Revenue (ttm)	3.93B +9.9%
Net Income	443.50M +28.2%
EPS	5.32 +28.2%
Shares Out	n/a
PE Ratio	29.19
Forward PE	12.86
Dividend	1.40 (0.95%)
Ex-Dividend Date	Jun 4, 2025

Volume	50
Average Volume	11
Open	158.20
Previous Close	159.10
Day's Range	157.50 - 158.20
52-Week Range	90.20 - 159.10
Beta	n/a
RSI	75.77
Earnings Date	Feb 12, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i...

• Industry: Pharmaceutical Preparations
• Founded: 1929
• Employees: 5,358
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I7G

Financial Performance

In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.